Please login to the form below

Not currently logged in
Email:
Password:

Sanofi SVP to become president and CEO of Teva Europe

Dr Rob Koremans will take over from Dr Gerard van Odijk

Rob Koremans - Teva EuropeSenior vice president, generic strategy and development, at Sanofi, Dr Rob Koremans, has been appointed president and CEO of Teva Europe.

Koremans will begin his new position in March 2012, when he will take over from Dr Gerard van Odijk who has held both positions for six years.

Van Odijk will remain with the company for the rest of 2012 to help with the transition.

Shlomo Yanai, who is to step down from his current position of president and CEO of Teva Pharmaceutical in May, commented on the announcement.

He said: “Under [van Odijk's] management, our business in Europe has been transformed as Teva became the undisputed generics leader in this major and growing market and established a strong position in speciality pharmaceuticals.

“I am very confident that Rob Koremans, together with our strong European management, will continue our success story across Europe.”

Prior to his current position at Sanofi, Koremans was CEO at Zentiva, the European generics business for Sanofi.

He has also been CEO of Cryo-Save, the stem cell storage company, and was vice president, Europe, of the Serono Group.

4th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics